Evidence map›Paper›PMID 39650051›Full record

ArticleClinical parkinsonism & related disorders2024

Effect of zonisamide on sleep and rapid eye movement sleep behavioral disorders in patients with Parkinson's disease: A randomized control trial.

Hiroshi Kataoka, Masahiro Isogawa, Hitoki Nanaura, Hiroyuki Kurakami, Miyoko Hasebe, Kaoru Kinugawa, Takao Kiriyama, Tesseki Izumi, Masato Kasahara, Kazuma Sugie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical parkinsonism & related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hiroshi KataokaDepartment of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Masahiro IsogawaInstitute for Clinical and Translational Science, Nara Medical University Hospital, Kashihara, Nara, Japan.
Hitoki NanauraDepartment of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Hiroyuki KurakamiInstitute for Clinical and Translational Science, Nara Medical University Hospital, Kashihara, Nara, Japan.
Miyoko HasebeInstitute for Clinical and Translational Science, Nara Medical University Hospital, Kashihara, Nara, Japan.
Kaoru KinugawaDepartment of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Takao KiriyamaDepartment of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Tesseki IzumiDepartment of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Masato KasaharaInstitute for Clinical and Translational Science, Nara Medical University Hospital, Kashihara, Nara, Japan.
Kazuma SugieDepartment of Neurology, Nara Medical University, Kashihara, Nara, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Zonisamide is a medication developed in Japan that is effective for motor symptoms and wearing off in Parkinson's disease (PD). Zonisamide has properties that may improve sleep disorders. The aim of this study is to verify the safety and efficacy of zonisamide for sleep disorders and rapid eye movement (REM) sleep behavioral disorders (RBD) using a mobile two-channel electroencephalography /electrooculography recording system in patients with PD. Methods: The present study is a single-blind randomized placebo-controlled trial. The subjects in the treatment group took zonisamide (25 mg per day) before bedtime. The primary outcome was sleep efficiency. The secondary endpoints were assessed as followed; objective outcomes of TST Results: Between the zonisamide and placebo groups, no significant differences were found in the primary outcome and secondary outcomes. Conclusions: The objective and subjective sleep metrics in this clinical trial did not significantly demonstrate zonisamide efficacy for sleep disorder in patients with PD. Although not significant, improvement in WASO and SOL was observed when zonisamide was compared with the placebo.

Indexed as

Clinical trialParkinsonREM sleep behavioral disordersSleepZonisamide

Identifiers

PMID39650051
PMCPMC11625216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.